close
  • Mega Menu Column
    • Facebook
    • Twitter
    • LinkedIn
    • Instagram
    • Donate
  • Home
  • About Us
    • Mission/Overview
    • Our Team
      • Board of Directors
      • Medical Advisors
      • Dental Advisory Council
      • Staff & Coaches
    • Financials
    • Contact Us
  • Living With P/P
    • Understanding P/P
    • All About Pemphigus (Patient Edition)
    • Pemphigoid
    • Diagnosis
    • Treatments
    • Rituxan
    • Find a Doctor
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
    • My Story
    • Ask A Coach
    • Discussion Forum
  • Research
    • Research Grants
    • Clinical Trials
    • Natural History Study (Patient Registry)
    • Clinically Speaking
      • All About Pemphigus (Physician Edition)
      • Pemphigoid
      • Treatments
      • Complications & Side Effects
      • Risk Factors
      • Diagnostic Testing
      • Current Consensus of Disease Outcomes
      • Prevention & Psychology
  • Get Involved
    • Patient Education Conference
    • Healing Heroes
    • Volunteer
    • Awareness
    • Support The IPPF
      • Make A Donation
      • Healing Heroes
      • Planned Giving
      • Other Ways To Give
    • Continuing Medical Education
    • Peer Support
      • Patient Education Series
      • Rare Connect
      • Ask A Coach
      • Local Support
  • News
    • PemPress
    • Quarterly
    • Events
    • The Coaches Corner
  •  Facebook
  •  Twitter
  •  Instagram
  • DONATE
Pemphigus Pemphigoid Foundation logoPemphigus Pemphigoid Foundation logo
  • Menu
  • About Us
    • Mission/Overview
    • Our Team
      • Board of Directors
      • Medical Advisors
      • Dental Advisory Council
      • Staff & Coaches
    • Financials
    • Employment
    • Contact Us
  • Living With P/P
    • Understanding P/P
    • All About Pemphigus (Patient Edition)
    • Pemphigoid
    • Diagnosis
    • Treatments
    • Rituxan
    • Find a Doctor
    • Prescription Assistance
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
    • My Story
    • Ask A Coach
    • Discussion Forum
  • Research
    • Research Grants
    • Clinical Trials
      • What is it?
      • Should I Volunteer?
      • What are my rights?
      • Definitions
    • Natural History Study (Patient Registry)
    • Clinically Speaking
      • All About Pemphigus (Physician Edition)
      • Pemphigoid
      • Treatments
      • Complications & Side Effects
      • Risk Factors
      • Diagnostic Testing
      • Current Consensus of Disease Outcomes
      • Prevention & Psychology
  • Get Involved
    • Patient Education Conference
    • Healing Heroes
    • Advocacy
      • Becoming a Self Advocate
      • Advocacy in Action!
      • Advocacy Tools and Resources
    • Awareness
    • Support The IPPF
      • Ways to Support
      • Make A Donation
      • Planned Giving
      • Volunteer
    • Continuing Medical Education
    • Peer Support
      • Patient Education Series
      • Discussion Forum
      • Local Support
      • Ask A Coach
  • News
    • PemPress
    • Quarterly
    • Events
    • The Coaches Corner

Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease

By Cristo Rey,

Posted by Cristo Rey

On August 19, 2012
Autoimmune bullous diseases (ABDs) are organ-specific autoimmune diseases, in which blisters on the skin and mucous membranes develop through binding of pathogenic autoantibodies to target antigens. There are two major ABD groups: the pemphigus group, showing autoantibodies to desmosomal components; and the subepidermal ABD group, showing autoantibodies to hemidesmosomal components in the epidermal basement membrane zone. Recent immunological, biochemical and molecular biological studies revealed many new autoantigens, including desmocollins, various plakin family proteins and integrins. A revised ABD classification includes new disease entities such as paraneoplastic pemphigus, IgA pemphigus and anti-laminin γ1 pemphigoid. In addition to systemic corticosteroids and various immunosuppressive agents, various adjuvant therapies for ABDs have developed. Among them, intravenous immunoglobulin (IVIG) is a promising therapy, although the therapeutic mechanisms are still unknown. Various disease models for ABDs have developed, particularly for pemphigus vulgaris, bullous pemphigoid and epidermolysis bullosa acquisita (EBA), and these have provided insights into the pathogenesis of various ADBs that suggest possible new treatment strategies. However, the fundamental mechanisms in disruption of immune-tolerance are still unknown. EBA shows autoimmunity to type VII collagen, the major component of anchoring fibrils, and EBA pathogenesis has been studied in various disease models. Previous studies suggested that, following binding of autoantibodies to type VII collagen, activation of complement, cytokine release, neutrophil migration, Fcγ receptors (FcgRs) and metalloproteinases play important roles in induction of subepidermal blisters. In this issue of the Journal of Pathology, Kasperkiewicz and colleagues reveal important roles of activating FcgRIV and inhibitory FcgRIIB in EBA pathogenesis that were recognized by conducting elegant studies using both genetic analysis and functional animal model methods. The expression equilibrium of the activating and inhibitory FcgRs can be modulated towards the inhibitory FcgRIIB by IVIG therapy, resulting in beneficial clinical effects of IVIG in EBA and other autoimmune skin-blistering diseases. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

http://onlinelibrary.wiley.com/doi/10.1002/path.4062/abstract

  • Facebook
  • Twitter
  • Google+
  • Pinterest
  • LinkedIn

Related

Cristo Rey

Tagged:autoimmune subepidermal bullous diseaseepidermolysispathogenesis

Post navigation

← PreviousClinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist
NextParaneoplastic pemphigus →
  • P/P Awareness Campaign
  • Disease Registry
  • Ask A Coach
  • Patients & Caregivers
  • For Medical Professionals
  • Clinical Trials
  • Treatments
  • @healourskin December 13, 2019

    If you live in the Southern New Jersey/Philadelphia area, register today to attend the first support group meeting… twitter.com/i/web/status/1…

  • @healourskin December 9, 2019

    We earned a Platinum Seal of Transparency by sharing the metrics that matter most! Check out our updated… twitter.com/i/web/status/1…

  • @healourskin December 7, 2019

    The IPPF recently presented at @WesternUNews to students in the College of Dental Medicine and College of Optometry… twitter.com/i/web/status/1…

  • @healourskin December 6, 2019

    There's still time to register for the upcoming Austin support group meeting on December 14th. Register today!… twitter.com/i/web/status/1…

  • @healourskin December 5, 2019

    Thank you to everyone that stopped by our booth at the @GNYDM and learned about the IPPF’s #BiopsiesSaveLives campa… twitter.com/i/web/status/1…

  • Volunteer
  • Careers
  • Donate
  • News
  • PemPress
  • Forums
  • Contact

About IPPF

The International Pemphigus & Pemphigoid Foundation’s most important objectives are to provide patients and doctors worldwide with information about pemphigus and pemphigoid, and to provide patients and their caregivers much needed comfort and support so they can continue to live active, productive lives.
Read more »

Contact Us

International Pemphigus & Pemphigoid Foundation
1331 Garden Highway, Ste 100
Sacramento, CA 95833
United States of America

info@pemphigus.org
(855) 473-6744
(916) 922-1298

© 2017 International Pemphigus & Pemphigoid Foundation · All rights reserved.
Privacy Policy | Terms of Use | Sitemap
Website design and implementation by Uptown Studios.
en English
ar العربيةbn বাংলাzh-CN 简体中文en Englishfr Françaisde Deutschel Ελληνικάiw עִבְרִיתhi हिन्दीit Italianoja 日本語fa فارسیpt Portuguêspa ਪੰਜਾਬੀru Русскийes Españolth ไทยvi Tiếng Việt

Cookies

Our site uses cookies. Find out more.